Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 22, Issue S1, Pages 69-76
Publisher
Wiley
Online
2020-04-08
DOI
10.1111/dom.13983
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
- (2019) Josef Coresh et al. Lancet Diabetes & Endocrinology
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis
- (2019) Hillel Sternlicht et al. CURRENT HYPERTENSION REPORTS
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors
- (2019) George L. Bakris AMERICAN JOURNAL OF KIDNEY DISEASES
- Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
- (2019) Hiromi Rakugi et al. HYPERTENSION RESEARCH
- Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
- (2019) Maria-Eleni Alexandrou et al. JOURNAL OF HYPERTENSION
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- SGLT2 Inhibitors and Mechanisms of Hypertension
- (2018) Alexandros Briasoulis et al. Current Cardiology Reports
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
- (2018) Robert M. Carey et al. HYPERTENSION
- Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials
- (2018) Fan Shunan et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
- (2018) Raquel González-Blázquez et al. Frontiers in Pharmacology
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- The Kidney in Hypertension
- (2017) Hillel Sternlicht et al. MEDICAL CLINICS OF NORTH AMERICA
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Nonsteroidal antagonists of the mineralocorticoid receptor
- (2015) Peter Kolkhof et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
- (2015) Peter Bramlage et al. EUROPEAN JOURNAL OF HEART FAILURE
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
- (2015) Licette CY Liu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
- (2014) Ivana Lazich et al. SEMINARS IN NEPHROLOGY
- Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
- (2013) Paul E. Stevens ANNALS OF INTERNAL MEDICINE
- The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?
- (2013) Johann Bauersachs EUROPEAN HEART JOURNAL
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
- (2012) Lars Bärfacker et al. ChemMedChem
- Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways
- (2012) Ana M. Briones et al. HYPERTENSION
- Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study
- (2012) Marcello Tonelli et al. LANCET
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Central regulation of blood pressure by the mineralocorticoid receptor
- (2011) Elise P. Gomez-Sanchez et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
- (2010) Jérôme Fagart et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
- (2009) U. F. Mehdi et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review
- (2008) Andrew S. Bomback et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
- (2008) Bertram Pitt et al. CIRCULATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now